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Abstract
The association of germline mutations in the breast cancer susceptibility gene 1 (BRCA1) and the breast cancer
susceptibility gene 2 (BRCA2) with the development of breast and ovarian cancers have been widely researched
and recognised. It is known that these genes function at multiple sites in the body. Research has subsequently
evolved into the connection of BRCA1/2 with cancers at other sites within the body. This review examines the
association of BRCA1/2 germline gene mutations with prostate, pancreatic and stomach cancers. An extensive
literature search revealed conflicting findings regarding the association of BRCA1/2 gene mutations with these
cancers. Most studies suggest that there is an association between BRCA1/2 mutations and carcinoma of the
prostate, pancreas and stomach, but some reports propose that such a correlation may be due to factors other
than possessing a mutated BRCA1/2 gene, and other associations may be revealed as further epidemiological
information becomes available. The review concludes that as more knowledge arises about the mechanisms of
BRCA1/2 gene mutations, it should pave the way for future screening programmes to be applied effectively.
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Introduction
One of the major advancements in cancer research was
the discovery of the breast cancer susceptibility gene 1
(BRCA1) and the breast cancer susceptibility gene 2
(BRCA2). Genetic abnormalities occur in all cancers
therefore, as BRCA1/2 pathways safeguard genetic con-
tent they are seen as critically important in research.
BRCA1/2 are tumour suppressor genes involved in path-
ways important for controlling DNA damage such as
recognition, transcription regulation and double-strand
break repair [1] and functions such as these are vital for
all cell types to avoid developing mutations. The mecha-
nisms by which BRCA1/2 mutations lead to cancer of
the breast and ovaries are not fully understood. One
possible explanation for the particular targeting of the
breasts and ovaries is that the epithelial tissue in these
areas is particularly vulnerable to transformation [2]. It
is known that BRCA1/2 genes function at multiple sites
throughout the body, not just in the breast and ovary.
From this knowledge, research on BRCA1/2 pathways
and their impact in other cancers has evolved.
BRCA1/2 genes are expressed in the cells of tissues
around the body. These genes have multiple functional
domains and interact with numerous proteins involved
in many biological processes. Thus, as BRCA proteins
function at a variety of sites, defects in DNA can occur
in these different sites leading to the development of
cancerous cells in tissues other than breast and ovarian
[3]. BRCA1 is reported to be involved in all phases of
the cell cycle and regulates events during cell progres-
sion. The normal functioning BRCA1 gene triggers cel-
lular responses to DNA damage that can block cell
proliferation and encourage apoptosis, subjecting cells to
a high risk of malignant transformation [4]. The BRCA2
gene is involved in repairing DNA. When mutations
occur in BRCA1/2 genes their normal function is
disrupted, therefore, DNA damage can accumulate in a
replicating cell resulting in the development of cancer-
ous tissues in the area of the body where the mutated
gene was situated [5].
Mutations in the BRCA1/2 genes are classified as
germline alterations since they are passed to subsequent
generations through the male and female gametes
(sperm and ovum respectively). The inheritable predis-
position of the BRCA1/2 genes for breast and ovarian
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cancers has been well established and widely researched.
After the discovery of BRCA1 on chromosome 17 [6] re-
searchers believed that at least one other cancer gene
was involved in hereditary breast and ovarian cancer
hence the identification and location of the BRCA2 gene
on chromosome 13 [7] triggered widespread interest in
genetic research and testing, leading to greater under-
standing of the mechanism underlying hereditary breast
cancer.
Over the years research has highlighted the link be-
tween mutations in BRCA1/2 genes and susceptibility to
breast and ovarian cancer. It has been established that a
woman’s risk of developing breast or ovarian cancer is
greatly increased if she carries a mutated BRCA1/2 gene
[8]. It is estimated that approximately 60 % of women
who carry a mutated BRCA1/2 gene will develop breast
cancer. Therefore, females with a mutated BRCA1/2
gene are five times more likely to develop breast cancer
than someone without a mutation [8, 9]. Nonetheless,
BRCA1/2 mutations are rare in the general population
and cause approximately 2 % of all breast cancers diag-
nosed [10]. The connection with BRCA1/2 gene muta-
tions and female breast and ovarian cancers has been
widely researched but not so for males. Until Edwards
et al. [11] reported that men who carry a mutated BRCA2
gene have an estimated 1 in 15 chance of developing
breast cancer before they reached 70 years no such con-
nections were made between males and BRCA1/2-related
hereditary breast cancer. Breast cancer in men remains
rare; latest statistics report approximately 350 cases of
male breast cancer in the UK in 2011 compared to almost
50,000 cases in women [12].
This report reviews the most relevant available litera-
ture on the association of BRCA1/2 genes with prostate,
pancreatic and stomach cancers.
Review
This review focuses on the association of mutations in
BRCA1/2 with carcinoma of the prostate, pancreas and
stomach and screening for BRCA1/2 gene mutations. It
is evident from the reviewed literature that the pancreas
and prostate were the two most important sites for
males who possess a BRCA1/2 mutation.
The impact of BRCA1/2 mutations for prostate cancer
When BRCA1/2 mutations were discovered it was ex-
tensively reported that these mutations played a role in
the development of breast and ovarian cancer. Since this
advancement, considerable research has investigated
whether BRCA1/2 mutations bestow risk of prostate
cancer. Familial aggregation of prostate cancer has been
described and the germline mutation of BRCA1/2 genes
has been implicated in some research studies [13]. To
date, many have reported on the association of both
BRCA1/2 mutations and some findings have indicated
extensively lower rates of survival and more aggressive
disease patterns [14, 15].
It is recognised that some prostate cancer diagnoses
have a poor prognosis and this has been connected with
hereditary factors [16]. The association between prostate
cancer and BRCA2 is consistent within research. Several
studies indicate that male carriers of BRCA2 are at an
increased risk of developing prostate cancer [13, 17]
while men with a BRCA1 mutation are believed to have
a slightly higher risk of developing prostate cancer than
those who possess no BRCA1/2 mutations. Early studies
reported BRCA1 mutation carriers to have a significant
increased relative risk of developing prostate cancer [18].
Men who carry a mutated BRCA2 gene are reported to
be seven times more likely to develop prostate cancer
than men who do not possess the mutation [19, 20]
BRCA2 is a multisite cancer gene that not only affects
women, but also increases a man’s risk of developing
cancer [17]. There is a recognised association of breast
cancer with prostate cancer within some families which
has been highlighted within several epidemiological
studies [21–23]. Agalliu et al. [24] found that risk of de-
veloping prostate cancer was particularly increased in
participants who possessed a mutated BRCA1 gene and
had a first-degree relative with prostate, breast or ovar-
ian cancer. Nonetheless, their findings showed that asso-
ciations between founder mutations and prostate cancer
were strong in men with no first-degree relative with
breast or ovarian cancer and were unaffected by family
history of prostate cancer [24]. Another study showed
that two of 290 participants with prostate cancer pos-
sessed germline protein-truncating BRCA2 mutations,
giving an overall prevalence of 0.69 %. Only one of these
participants reported a first-degree relative with prostate
cancer and neither of the two participants reported a
family history of breast or ovarian cancer [25].
Bermejo and Hemminki [26] demonstrated that fam-
ilies with bi-lateral breast cancer diagnosed before aged
50 years presented increased standard incidence ratios
for prostate cancers. Edwards et al. [27] found that 18 %
of participants in their study had a first-degree relative
with prostate cancer. It was calculated that BRCA2 mu-
tations amount for approximately 6 % of the increased
familial risk of prostate cancer. This suggests that while
associations have been established, the overall contribu-
tion of BRCA2 mutations to the familial aggregation of
prostate cancer is small.
Prostate cancer risk and age at diagnosis
It is frequently hypothesised that the risk of prostate
cancer associated with mutations in BRCA1/2 varies by
age at diagnosis. Previously, an increased incidence was
reported in men with BRCA2 mutations and prostate
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cancer that were diagnosed before 65 years [20]. In some
studies the risk of prostate cancer associated with
BRCA1/2 mutations is reported higher in men diagnosed
at an older age [24]. Some studies also suggest that men
with prostate cancer who harbour BRCA1/2 mutations
are believed to develop the disease at an early age. In the
study by Agalliu et al. [24] participants were stratified into
two groups: cases at age of diagnosis <65 and >65 years of
age. Their findings demonstrated no associations of the
founder mutations in the <65 year age group. They also
showed a statistically significant result between the age
group >65 years at prostate diagnosis and BRCA1. Edwards
et al. [27] used the average of the estimated prevalence
(0.12 and 0.07 %) of disease associated BRCA2 mutations
within the general UK population. It was reported that
50 % of the six prostate cancer patients carrying BRCA2
mutations were diagnosed before aged 50 years. Similarly
Agalliu et al. [25] reported the existence of aggressive pros-
tate tumours developing at an early-onset, less than
55 years. This implies that screening may be required at a
younger age among BRCA1/2 mutation carriers.
Most often, the association between BRCA1/2 muta-
tions is assessed according to clinical features. In a study
by Agalliu et al. [24] it was established that carriers of
any of the three founder mutations in BRCA1/2 were as-
sociated with an increased risk in developing high grade
prostate cancer. Results showed that BRCA2 mutation
carriers had a 3.2-fold increased risk of high grade pros-
tate cancer. In analysis by Edwards et al. [11] a loss of
heterozygosity was evident in the five available prostate
cancer tumours from group one which indicated a rela-
tionship between BRCA2 germline mutations and pre-
disposition to prostate cancer in these individuals.
BRCA1/2 mutations and prostate cancer survival rate
Within the research it appears evident that a poorer sur-
vival rate is greatly associated with BRCA2 germline mu-
tations. Narod et al. [17] compared the survival of men
with a BRCA1 mutation with prostate cancer with that
of men with a BRCA2 mutation and prostate cancer and
found a significant difference in results. The median sur-
vival from diagnosis for BRCA1 was 8.0 years compared
to BRCA2 which was 4.0 years. A similar prevalence was
detected in the cohort study by Edwards et al. [11]
where the median survival of prostate cancer patients
with a BRCA2 mutation was 4.8 years whereas the me-
dian survival in controls was 8.5 years.
Edwards et al. [27] found that five of their six partici-
pants carrying BRCA2 mutations had no family history
of prostate cancer and four participants had no family
history of breast cancer. This suggests BRCA2 may be a
high risk prostate cancer susceptibility gene. The results
also have potential implications for the management of
early-onset prostate cancer. It would be reasonable to
suggest that such individuals should be offered referral
to screening programmes. Utilising this cohort study by
Edwards et al. [27], further research was undertaken by
the group [11] comparing this cohort with a clinical set
from Manchester, UK, of known BRCA2 mutation car-
riers with prostate cancer. A small sample of men who
possessed a BRCA2 mutation and were diagnosed with
prostate cancer at less than 55 years were compared
with men diagnosed at a similar age but without a mu-
tated BRCA2 gene. Findings concluded that germline
mutations in BRCA2 are an independent prognostic fac-
tor for survival in prostate cancer. Such results highlight
the importance of developing targeted chemotherapies
to treat prostate cancer in men with BRCA2 mutations
[17]. This may be an important factor to consider for fu-
ture research into treatment.
BRCA1/2 mutations in pancreatic cancer
Pancreatic cancer is a disease with poor prognosis and
low survival rates worldwide. Its mortality compares
strikingly with its incidence. In the UK in 2011, there
were 8,773 diagnosed cases and a mortality rate of 8,320
[28]. Through analysis of the literature it was found that
both BRCA1 and BRCA2 mutations are associated with
the incidence of pancreatic cancer and that BRCA2 mu-
tation poses an increased risk for developing pancreatic
cancer [29]. Furthermore environmental and genetic fac-
tors have been proposed as causes of the pancreatic can-
cer with the genetic factor of particular importance
believed to be the BRCA2 gene [30].
It has been reported that pancreatic cancer is the third
most common cancer associated with BRCA1/2 muta-
tions [31]. The risk of pancreatic cancer increases in the
individual who has a close relative with the disease. Ap-
proximately 5-10 % of pancreatic cancer cases are be-
lieved to show familial clustering [32]. As with prostate
cancer incidence [27], it has been suggested that patients
with pancreatic cancer and germline BRCA2 mutations
tend to be of Ashkenazi Jewish decent and have a youn-
ger than average age of onset [33]. Recently, evidence of
a strong family history of pancreatic cancer was reported
in a study among 211 Ashkenazi Jewish probands.
Within the sample, 31 % had a first-degree relative with
pancreatic cancer, 53 % had a second-degree relative and
16 % had a third-degree relative diagnosed with the dis-
ease; furthermore 26 of the 211 probands had more than
one relative diagnosed with pancreatic cancer [29]. It is
important to acknowledge that the study participants are
of Ashkenazi Jewish decent therefore, it would be rea-
sonable to assume that BRCA1/2 mutation prevalence
may be increased among this sample.
It is clear that BRCA1/2 mutations are evident in
many familial breast-pancreas cancer families and that
carriers of the BRCA2 mutation have an increased risk
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of developing pancreatic cancer [29]. Nonetheless, the
degree to which family history of pancreatic cancer in-
fluences the likelihood of detecting a BRCA1/2 mutation
in an individual with breast cancer is less clear [29]. Per-
haps, differences in population samples can account for
conflicting results within studies making it difficult to
make a connection. Furthermore, the use of different
analysis models within studies can lead to variations in
mutation prevalence.
Pancreatic cancer has been regarded as a component
of the breast-ovarian cancer syndrome [29]. In a study
by Axilbund et al. [34] over half the study population re-
ported a family history of breast and/or ovarian cancer
in addition to pancreatic cancer. The study findings sug-
gest that BRCA1 mutations are not a substantial cause
of breast cancer in familial pancreatic cancer kinships as
none of the participants were found to possess a BRCA1
mutation from DNA sequencing.
Stadler et al. [29] demonstrated that 70 families had
more than two relatives diagnosed with breast cancer
within the same pedigree as the family history of pancre-
atic cancer and 31 probands had a relative with ovarian
cancer within the same family tree. Axilbund et al. [34]
showed that from a sample of 66 pancreatic cancer pa-
tients, four reported having had breast cancer prior to
being diagnosed with pancreatic cancer. Conversely, in a
cohort study by Tulinius et al. [35] no familial risk due
to BRCA2 gene mutations was found for pancreatic cancer
among breast cancer patients, yet, it was evident for can-
cers of the stomach, prostate and kidneys. These results
could suggest that specific regions of BRCA1/2 genes may
have increased associations with particular cancers.
Kim et al. [36] reviewed the pedigrees of 1312 families
tested for a BRCA1/2 mutation; 219 families were posi-
tive for BRCA1 mutations and 156 families had BRCA2
mutations. Results showed that 11 % of the 219 BRCA1
positive families had at least one relative with pancreatic
cancer and 2.7 % had more than one relative with pan-
creatic cancer. Stadler et al. [29] identified 14.2 %
BRCA1/2 mutations among the sample of 211 Ashkenazi
Jews who reported a personal history of breast cancer
and a family history of pancreatic cancer. Furthermore,
Bermejo and Hemminki [26] demonstrated that families
of patients with breast cancer diagnosed before aged
35 years presented significant standard incidence ratios (a
ratio that allows comparison of incidence rates among dif-
ferent populations) for pancreatic cancers. However, this
standard incidence ratio was reported to be indicative of
some association of early-onset breast cancer and pancre-
atic cancer through causes unrelated to BRCA1 mutations,
although no other proposed causes were suggested.
The findings from the Stadler study [29] demonstrated
that approximately 64 % of the relatives with pancreatic
cancer were female and 24 % of these women also had a
previous diagnosis of breast cancer. Two male relatives,
one from a BRCA1 positive family and one from a
BRCA2 positive family, were diagnosed with both breast
and pancreatic cancer. However, the findings from this
study suggest that the distribution of BRCA1 (47 %) and
BRCA2 (53 %) mutations is nearly equal in Ashkenazi
Jewish breast-pancreas cancer families who possess a
mutation. Conversely, in the study by Axilbund et al.
[34], BRCA1 mutations were not identified despite over
half of the pancreatic cancer probands reporting a family
history of breast and ovarian cancer. Since the preva-
lence of BRCA1/2 gene mutations in the general popula-
tion is small not all familial clustering of cancers can be
associated with mutations in these genes. A strong fam-
ily history could be attributed to other inheritable factors
or lifestyle choices within families.
As with prostate cancer [25], it has been suggested
that pancreatic cancer patients who possess a mutated
BRCA2 gene have a younger age of onset [20]. Kim et al.
[36] reported the mean age of diagnosis of pancreatic
cancer within BRCA1 positive families was 62.9 years.
The median age for males among this group was 59 years
and 68 years in females. Within BRCA2 positive families
the mean age at diagnosis was also 62.9 years, while the
median age in males was 67 years and 59 years in females.
These results support the findings by Stadler et al. [29]
where the mean age for diagnosis of pancreatic cancer
among the relatives was 67.4 years. This is typically
older than the average age at which BRCA1/2-related
breast and ovarian cancers occur. However, 24 % of the
females previously had breast cancer before developing
pancreatic cancer.
BRCA1/2 mutations in stomach cancer
Stomach cancer represents a significant global cancer
burden and BRCA1/2 mutations have been reported to
increase the lifetime risk of developing stomach cancer by
as much as 6-fold greater among first-degree relatives of
BRCA1/2 mutation carriers [20, 37]. The risk is reported
to be 4-fold greater in BRCA1 mutation carriers [38] and
at least 2-fold greater in BRCA2 mutation carriers [35].
As with pancreatic cancer [26], familial aggregations of
breast cancer and stomach cancer have been highlighted.
In a Polish study evaluating the importance of a family
history of stomach cancer in predicting the presence of a
BRCA2 mutation in patients with ovarian cancer, findings
showed that 8 of 34 women with ovarian cancer and a
family history of stomach cancer were found to carry a
BRCA2 mutation versus 3 of 75 women with ovarian can-
cer and a family history of ovarian cancer but not stomach
cancer [39]. In a further study, Jakubowska et al. [40] ana-
lysed DNA to determine the frequency and nature of
BRCA2 germline mutations in Polish families where there
was a clear aggregation of breast and male stomach
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cancers occurring at an early age. 29 families with an ag-
gregation of at least one female diagnosed with breast can-
cer before aged 50 years and one male diagnosed with
stomach cancer before aged 55 years participated in the
study. They demonstrated that in 12 of 28 families, stom-
ach cancer was diagnosed in a first-degree relative of an
early-onset breast cancer proband [40]. This highlights the
importance of family history in surveillance.
Tulinius et al. [35] conducted a cohort study using
record linkage of breast cancer families to estimate the
risk of malignant diseases in families of probands with
the same BRCA2 mutation. Of the 995 probands in the
study, 887 were tested for the mutation. 797 tested nega-
tive for the BRCA2 mutation and 90 (10.1 %) tested
positive. The relative risk of stomach cancer was signifi-
cantly increased among the BRCA2 mutation positive
cohort and was reported to be 2.40-fold for first-degree
relatives and 1.91-fold for second-degree relatives. Simi-
larly, Bermejo and Hemminki [26] demonstrated that
the incidence of individuals affected with stomach can-
cer before aged 70 years in families with breast and ovar-
ian cancer was 1.88 %, which is significantly higher than
in the general population.
Schlebusch et al. [41] demonstrated that stomach can-
cer prevalence was significantly increased in BRCA2 mu-
tation families compared to the general population.
However, previous to this, van Asperen et al. [42] re-
ported no significant increased risk of developing stom-
ach cancer in their study on cancer risks in Dutch
BRCA2 families. However, Ashkenazi Jews represented
15.5 % of the sample in the Schlebusch study [41] which
may have implications for their increased prevalence yet
many of their participants were reported to be of Dutch
decent. It has been suggested that the frequency of
stomach cancer appears greater among Polish families
with BRCA2 mutations [40] but again this could be due
to a higher proportion of participants of Jewish decent.
The findings from this previous study showed that in
the occurrence of breast and stomach cancer among
first-degree relatives, BRCA2 mutations were detected in
16.7 %. Findings from the Jakubowska study [39] suggest
the presence of a germline BRCA2 mutation among
these families given the incidence of ovarian and stom-
ach cancer among families in the Polish population. It
also confirms stomach cancer is among the range of dis-
eases attributable to BRCA2 mutations. Figer et al. [43]
previously reported the frequency of BRCA2 mutations
among 70 consecutive Ashkenazi Jewish patients with
stomach cancer was 5.7 %, approximately five times
higher than the general population. Furthermore, Jaku-
bowska et al. [40] showed that BRCA2 abnormalities
were detected in 16.7 % in families where breast and
stomach cancers occurred among first-degree relatives
and BRCA2 mutations were identified among 23.5 % in
families where stomach cancer occurred among second-
degree relatives.
It has previously been suggested that the increased fre-
quency of stomach cancers in BRCA2 carriers may be
sex related as it has been reported to occur primarily in
males [20]. In the population based study by Bermejo
and Hemminki [26] almost all the individuals diagnosed
with stomach cancer in families with breast and ovarian
cancers were males. Findings showed that 23 families
with breast, ovarian and stomach cancers included 23
men and 1 woman with stomach cancer [26]. It could be
argued that as BRCA1/2 mutations in women can lead
to early-onset breast cancer, individuals who develop
breast or ovarian cancers early in life may not survive to
develop stomach cancer in later life.
The findings from the Polish study by Jakubowska
et al. [39] highlight the need for future research to estab-
lish if there is a region on the BRCA2 gene associated
with a particularly high risk of stomach cancer. However,
a major weakness of these findings is that when con-
structing pedigrees, cancers in relatives were based on
patient recall and pathological confirmation was gener-
ally not available. Therefore, it is possible that the risk of
stomach cancer in this study may be overestimated or
underestimated.
Impact of BRCA1/2 mutations in other associated cancers
Previous studies have highlighted an association with
BRCA1/2 gene mutations and an increased risk of devel-
oping cancer in sites other than the breast and ovary. The
association of BRCA1/2 gene mutations with cancer of the
prostate, pancreas and stomach has been demonstrated in
a number of studies as discussed in this review. However,
carcinomas of the colon and kidneys, as well as malignant
melanoma, have also been reported to be linked with mu-
tations in the BRCA1/2 genes [20, 44]. Nonetheless, the
absolute risks for cancer developing at these other sites
are small [19]. The strengths of the associations may be
difficult to estimate due to the lower reported incidence of
these cancers in mutation carriers.
Screening for BRCA1/2 mutations
After the discovery of mutations in BRCA1/2 genes,
widespread interest in genetic testing developed among
women at risk of harbouring a disease-associated muta-
tion [45]. Screening and genetic testing has the poten-
tial to cause unease within a family as the impact of
receiving a positive BRCA mutation diagnosis not only
has implications for the carrier, but all family members.
Additionally, in some countries, screening for BRCA1/2
mutations can result in implications for health and life
insurances.
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Implications for male BRCA1/2 mutation carriers
Kim et al. [36] report that in most BRCA1/2 testing pro-
grammes less than 10 % of the individuals tested are
men, yet there is an equal gender distribution in the
population of male and female BRCA1/2 mutation car-
riers. It is argued that BRCA1/2 mutation screening may
be of greater relevance to females as the risks of cancer
are greatly elevated in female BRCA1/2 mutation carriers
compared to male [37], however the findings of this review
highlight that there are cancer risks for male carriers of
BRCA1/2 mutations therefore screening has relevance for
men in their own right, rather than just to inform risk for
relatives.
Several motivation factors prompt individuals to undergo
genetic screening. In a study by Daly et al. [45] 23 of 26 par-
ticipants cited concern for their offspring as their main mo-
tivation to undergo screening. Concerns about transmitting
a mutated gene to daughters appeared to be a major motiv-
ating factor. Results reported by Hallowell et al. [46] gener-
ated similar findings and found that all men underwent
genetic testing with the intention of providing information
for their children.
Conclusions
This review examined freely available, full-text, literature
reporting on the impact of both BRCA1 and BRCA2
gene mutations and their impact on cancers other than
breast or ovarian cancers and identified three main can-
cers, (other than breast and ovarian,) associated with
germline mutations in BRCA1/2 genes. The majority of
the literature proposes an association between BRCA1/2
mutations and carcinoma of the prostate, pancreas and
stomach. Analysis of the selected literature suggests that
mutation of the BRCA2 gene, rather than BRCA1 gene,
has a greater influence on the risk of developing prostate,
pancreas and stomach cancers, as well as impacting on
the survival and age of onset of these cancers. However,
some research has suggested that while there are evident
connections between breast and ovarian, and prostate,
pancreatic or stomach cancers, it is possible that such
links may be due to factors other than possessing a mu-
tated BRCA1/2 gene. Other associations may be revealed
as further epidemiological information becomes available.
Detailed examination of the literature revealed con-
flicting findings regarding the association of mutated
BRCA1/2 genes with familial aggregation of cancers as-
sociated with these genes. A number of studies indicated
BRCA1/2 gene mutations are associated with familial ag-
gregation of cancer. Furthermore, interactions have been
established between mutation carrier status of BRCA1/2
genes and first-degree family history of cancer. Nonethe-
less, conflicting findings are evident as other studies
demonstrated BRCA1/2 mutations were not a major
cause of aggregation of cancer in families.
Analysis of the literature identified a number of studies
implicating mutated BRCA1/2 genes were responsible
for a significant fraction of prostate, pancreatic and
stomach cancer development, as well as susceptibility to
advanced disease. Confirmed associations of BRCA1/2
gene mutations with prostate, pancreatic and stomach
cancer at a population level have been reported within
the research. Nonetheless, some studies have suggested
that only a very small proportion of early-onset cancer
in the general population is attributed to BRCA1/2 gene
mutations. It is important to note that because family
members share a quantity of their genes and often their
environment, it is possible that the large number of can-
cer cases present in these families may be due in part to
other genetic or environmental factors rather than pos-
sessing a BRCA1/2 gene mutation.
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